Common pathophysiological mechanisms of chronic kidney disease: Therapeutic perspectives

Pharmacology and Therapeutics

Volumn 128, Issue 1, 2010, Pages 61-81

  López Novoa, José M ^b,d   Martínez Salgado, Carlos ^a,b,d   Rodríguez Peña, Ana B ^c   Hernández, Francisco J López ^a,b,d  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Instituto Reina Sofía de Investigación Nefrológica   (Spain)

Author keywords

Animal models; Chronic renal disease; Diabetes; Hypertension; Renal mass reduction; Therapy; Ureteral obstruction

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ADVANCED GLYCATION END PRODUCT; ALISKIREN; AMLODIPINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APAFANT; AS 602801; AVOSENTAN; BENAZEPRIL; BRADYKININ; CANDESARTAN; CEP 1347; DILTIAZEM; ENALAPRIL; EPROSARTAN; FOSINOPRIL; FR 165673; GW 788388; HYALURONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IN 1130; INCB 18424; IRBESARTAN; LISINOPRIL; LOSARTAN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; NPC 31145; OLMESARTAN; PIRINIXIC ACID; PROTEIN KINASE C; RAMIPRIL; REACTIVE OXYGEN METABOLITE; TELMISARTAN; TEZOSENTAN; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UR 12670; VALSARTAN; VERAPAMIL;

ANTIINFLAMMATORY ACTIVITY; AUTOREGULATION; CELL FATE; CELL INFILTRATION; CELL PROLIFERATION; CELL THERAPY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; DIABETIC NEPHROPATHY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; ETHNIC DIFFERENCE; FOCAL GLOMERULOSCLEROSIS; GENE THERAPY; GENETIC POLYMORPHISM; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTENSIVE NEPHROPATHY; KIDNEY BLOOD FLOW; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE EPITHELIUM; MESANGIUM CELL; MESENCHYME CELL; OBSTRUCTIVE NEPHROPATHY; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEINURIA; RENAL MASS REDUCTION; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; REVIEW; SIGNAL TRANSDUCTION; URINARY TRACT OBSTRUCTION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; NEPHRONS; RENAL INSUFFICIENCY, CHRONIC;

EID: 79551643220     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.05.006     Document Type: Review

References (323)

1. Abernethy D.R., Schwartz J.B. Calcium anagonist drugs. N Engl J Med 1999, 341:1447-1457.
2. Aiello S., Remuzzi G., Noris M. Nitric oxide/endothelin balance after nephron reduction. Kidney Int Suppl 1998, 65:S63-S67.
3. Akagi Y., Isaka Y., Arai M., Kaneko T., Takenaka M., Moriyama T., Kaneda Y., Ando A., Orita Y., Kamada T., Ueda N., Imai E. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996, 50:148-155.
4. Anglani F., Forino M., Del Prete D., Tosetto E., Torregrossa R., D'Angelo A. In search of adult renal stem cells. J Cell Mol Med 2004, 8:474-487.
5. Ardaillou R., Chansel D., Chatziantoniou C., Dussaule J.C. Mesangial AT1 receptors: Expression, signaling, and regulation. J Am Soc Nephrol 1999, 10:S40-S46.
6. Aunapuu M., Pechter U., Arend A., Suuroja T., Ots M. Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment. Medicina (Kaunas) 2003, 39:975-979.
7. Azizi M., Webb R., Nussberger J., Hollenberg N.K. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens 2006, 24:243-256.
8. Bagate K., Develioglu L., Grima M., De Jong W., Simmons W.H., Imbs J.L., Barthelmebs M. Vascular catabolism of bradykinin in the isolated perfused rat kidney. Eur J Pharmacol 2000, 407:317-325.
9. Bagnis C., Deray G., Dubois M., Pirotzky E., Jacquiaud C., Baghos W., Aupetit B., Braquet P., Jacobs C. Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist. Nephrol Dial Transplant 1996, 11:507-513.
10. Bascands J.L., Schanstra J.P. Obstructive nephropathy: Insights from genetically engineered animals. Kidney Int 2005, 68:925-937.
11. Becker B.N., Yasuda T., Kondo S., Vaikunth S., Homma T., Harris R.C. Mechanical stretch/relaxation stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Exp Nephrol 1998, 6:57-66.
12. Bellin C., de Wiza D.H., Wiernsperger N.F., Rosen P. Generation of reactive oxygen species by endothelial and smooth muscle cells: Influence of hyperglycemia and metformin. Horm Metab Res 2006, 38:732-739.
13. Benchetrit S., Mandelbaum A., Bernheim J., Podjarny E., Green J., Katz B., Rathaus M. Altered vascular reactivity following partial nephrectomy in the rat: A possible mechanism of the blood-pressure-lowering effect of heparin. Nephrol Dial Transplant 1999, 14:64-69.
14. Benfield M.R., McDonald R.A., Bartosh S., Ho P.L., Harmon W. Changing trends in pedriatric transplantation: 2001 annual report of the north american pediatric renal transplant cooperative study. Pediatr Transplant 2003, 7:321-335.
15. Bernstein K.E., Sayeski P.P., Doan T., Farmer P.K., Ali M.S. Signal transduction pathways of angiotensin II in the kidney. Contrib Nephrol 2001, 135:16-33.
16. Berry C., Touyz R., Dominiczak A.F., Webb R.C., Johns D.G. Angiotensin receptors: Signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001, 281:H2337-H2365.
17. Bianco P., Gehron Robey P. Marrow stromal stem cells. J Clin Invest 2000, 105:1663-1668.
18. Bidani A.K., Hacioglu R., Abu-Amarah I., Williamson G.A., Loutzenhiser R., Griffin K.A. "Step" vs. "dynamic" autoregulation: Implications for susceptibility to hypertensive injury. Am J Physiol Ren Physiol 2003, 285:F113-F120.
19. Bolick D.T., Hatley M.E., Srinivasan S., Hedrick C.C., Nadler J.L. Lisofylline, a novel antiinflammatory compound, protects mesangial cells from hyperglycemia- and angiotensin II-mediated extracellular matrix deposition. Endocrinology 2003, 144:5227-5231.
20. Bonventre J.V. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003, 14(Suppl 1):S55-S61.
21. Brandis A., Bianchi G., Reale E., Helmchen U., Kuhn K. Age-dependent glomerulosclerosis and proteinuria occurring in rats of the Milan normotensive strain and not in rats of the Milan hypertensive strain. Lab Invest 1986, 55:234-243.
22. Brenner B.M. Nephron adaptation to renal injury or ablation. Am J Physiol 1985, 249:F324-F337.
23. Brewster U.C., Perazella M.A. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004, 116:263-272.
24. Brezniceanu M.L., Liu F., Wei C.C., Chénier I., Godin N., Zhang S.L., Filep J.G., Ingelfinger J.R., Chan J.S. Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes 2008, 57:451-459.
25. Brodie J.C., Humes H.D. Stem cell approaches for the treatment of renal failure. Pharmacol Rev 2005, 57:299-313.
26. Brown N.J., Kumar S., Painter C.A., Vaughan D.E. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 2002, 40:859-865.
27. Brown D.M., Provoost A.P., Daly M.J., Lander E.S., Jacob H.J. Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. Nat Genet 1996, 12:44-451.
28. Bruzzi I., Corna D., Zoja C., Orisio S., Schiffrin E.L., Cavallotti D., Remuzzi G., Benigni A. Time course and localization of endothelin-1 gene expression in a model of renal disease progression. Am J Pathol 1997, 151:1241-1247.
29. Camp T.M., Smiley L.M., Hayden M.R., Tyagi S.C. Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens 2003, 21:1719-1727.
30. Cao Z., Bonnet F., Candido R., Nesteroff S.P., Burns W.C., Kawachi H., Shimizu F., Carey R.M., De Gasparo M., Cooper M.E. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002, 13:1773-1787.
31. Carl M., Akagi Y., Weidner S., Isaka Y., Imai E., Rupprecht H.D. Specific inhibition of Egr-1 prevents mesangial cell hypercellularity in experimental nephritis. Kidney Int 2003, 63:1302-1312.
32. Chatziantoniou C., Dussaule J.C. Insights into the mechanisms of renal fibrosis: Is it possible to achieve regression?. Am J Physiol Ren Physiol 2005, 289:F227-F234.
33. Chen C., Xia S.H., Chen H., Li X.H. Therapy for acute pancreatitis with platelet-activating factor receptor antagonists. World J Gastroenterol 2008, 14:4735-4738.
34. Chevalier R.L. Pathophysiology of obstructive nephropathy in the newborn. Semin Nephrol 1998, 18:585-593.
35. Chevalier R.L., Forbes M.S., Thornhill B.A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009, 75:1145-1152.
36. Chien S. Mechanotransduction and endothelial cell homeostasis: The wisdom of the cell. Am J Physiol Heart Circ Physiol 2007, 292:H1209-H1224.
37. Choi Y.J., Mendoza L., Rha S.J., Sheikh-Hamad D., Baranowska-Daca E., Nguyen V., Smith C.W., Nassar G., Suki W.N., Truong L.D. Role of p53-dependent activation of caspases in chronic obstructive uropathy: evidence from p53 null mutant mice. J Am Soc Nephrol 2001, 12:983-992.
38. Cohen M.P., Masson N., Hud E., Ziyadeh F., Han D.C., Clements R.S. Inhibitin albumin glycation ameliorated diabetic nephropathy in the db/db mouse. Exp Nephrol 2000, 8:135-143.
39. Connolly S.B., Sadlier D., Kieran N.E., Doran P., Brady H.R. Transcriptome profiling and the pathogenesis of diabetic complications. J Am Soc Nephrol 2003, 14(8 Suppl 3):S279-S283.
40. Cortes P., Riser B.L., Yee J., Narins R.G. Mechanical strain of glomerular mesangial cells in the pathogenesis of glomerulosclerosis: Clinical implications. Nephrol Dial Transplant 1999, 14:1351-1354.
41. Cortes P., Zhao X., Riser B.L., Narins R.G. Regulation of glomerular volume in normal and partially nephrectomized rats. Am J Physiol 1996, 270:F356-F370.
42. Dai T., Natarajan R., Nast C.C., LaPage J., Chuang P., Sim J., Tong L., Chamberlin M., Wang S., Adler S.G. Glucose and diabetes: Effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. Kidney Int 2006, 69:806-814.
43. Davis B.B., Thomasson D., Zenser T.V. Renal disease profoundly alters cortical interstitial cell function. Kidney Int 1983, 23:458-464.
44. De Zeeuw D., Hillege H.L., de Jong P.E. The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl 2005, 68(Suppl. 98):S25-S29.
45. Di Paolo S., Gesualdo L., Ranieri E., Grandaliano G., Schena F.P. High glucose concentration induces the overexpression of transforming growth factor-beta through the activation of a platelet-derived growth factor loop in human mesangial cells. Am J Pathol 1996, 149:2095-2106.
46. Diabetes Control and Complications-DCCT Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995, 47:1703-1720.
47. Diamond J.R. Macrophages and progressive renal disease in experimental hydronephrosis. Am J Kidney Dis 1995, 26:133-140.
48. Diamond J.R., Kees-Folts D., Ding G., Frye J.E., Restrepo N.C. Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis. Am J Physiol 1994, 266:F926-F933.
49. Diamond J.R., Kreisberg R., Evans R., Nguyen T.A., Ricardo S.D. Regulation of proximal tubular osteopontin in experimental hydronephrosis in the rat. Kidney Int 1998, 54:1501-1509.
50. Doggrell S.A. Bradykinin B2 receptors-A target in diabetic nephropathy. Expert Opin Ther Targets 2005, 9:411-414.
51. Doi K., Okamoto K., Negishi K., Suzuki Y., Nakao A., Fujita T., Toda A., Yokomizo T., Kita Y., Kihara Y., Ishii S., Shimizu T., Noiri E. Attenuation of folic acid-induced renal inflammatory injury in platelet-activating factor receptor-deficient mice. Am J Pathol 2006, 168:1413-1424.
52. Dos Santos O.F., Boim M.A., Barros E.J., Schor N. Role of platelet activating factor in gentamicin and cisplatin nephrotoxicity. Kidney Int 1991, 40:742-747.
53. Durvasula R.V., Petermann A.T., Hiromura K., Blonski M., Pippin J., Mundel P., Pichler R., Griffin S., Couser W.G., Shankland S.J. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004, 65:30-39.
54. Ekinci S., Ciftci A.O., Atilla P., Muftuoglu S., Senocak M.E., Buyukpamukcu N. Ureteropelvic junction obstruction causes histologic alterations in contralateral kidney. J Pediatr Surg 2003, 38:1650-1655.
55. El Nahas A.M. Growth factors and glomerular sclerosis. Kidney Int Suppl 1992, 36:S15-S20.
56. Endlich N., Kress K.R., Reiser J., Uttenweiler D., Kriz W., Mundel P., Endlich K. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 2001, 12:413-422.
57. Endlich N., Sunohara M., Nietfeld W., Wolski E.W., Schiwek D., Kranzlin B., Gretz N., Kriz W., Eickhoff H., Endlich K. Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J 2002, 16:1850-1852.
58. Epstein M. Calcium antagonists and the kidney. Implications for renal protection. Am J Hypertens 1993, 6:251S-259S.
59. Epstein M. Evolving therapeutic strategies for retarding progression of diabetic nephropathy-An update for 2002. Acta Diabetol 2002, 39(Suppl 2):S41-S45.
60. Epstein M. Recent landmark clinical trials: How do they modify the therapeutic paradigm?. Am J Hypertens 2002, 15:82S-84S.
61. Excerpts from the United States Renal Data System's 2000 annual data report: Atlas of end-stage renal disease in the United States. Am J Kiney Dis 2000, 36(Suppl. 2):S1-S137.
62. Fan Y.P., Weiss R.H. Exogenous attenuation of p21(Waf1/Cip1) decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1. J Am Soc Nephrol 2004, 15:575-584.
63. Floege J., Alpers C.E., Burns M.W., Pritzl P., Gordon K., Couser W.G., Johnson R.J. Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Lab Invest 1992, 66:485-497.
64. Floege J., Burns M.W., Alpers C.E., Yoshimura A., Pritzl P., Gordon K., Seifert R.A., Bowen-Pope D.F., Couser W.G., Johnson R.J. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 1992, 41:297-309.
65. Floege J., Johnson R.J., Couser W.G. Mesangial cells in the pathogenesis of progressive glomerular disease in animal models. Clin Invest 1992, 70:857-864.
66. Flores O., Arevalo M., Gallego B., Hidalgo F., Vidal S., Lopez-Novoa J.M. Beneficial effect of the long-term treatment with the combination of an ACE inhibitor and a calcium channel blocker on renal injury in rats with 5/6 nephrectomy. Exp Nephrol 1998, 6:39-49.
67. Flyvbjerg A., Denner L., Schrijvers B.F., Tilton R.G., Mogensen T.H., Paludan S.R., Rasch R. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004, 53:166-172.
68. Fogo A.B. New insights into the renin-angiotensin system and hypertensive renal disease. Curr Hypertens Rep 1999, 1:187-194.
69. Fogo A.B. Progression versus regression of chronic kidney disease. Nephrol Dial Transplant 2006, 21:281-284.
70. Fogo A.B. Can glomerulosclerosis be reversed?. Nat Clin Pract Nephrol 2006, 2:290-291.
71. Frokiaer J., Djurhuus J.C., Nielsen M., Pedersen E.B. Renal hemodynamic response to ureteral obstruction during converting enzyme inhibition. Urol Res 1996, 24:217-227.
72. Garber S.L., Mirochnik Y., Brecklin C., Slobodskoy L., Arruda J.A., Dunea G. Effect of relaxin in two models of renal mass reduction. Am J Nephrol 2003, 23:8-12.
73. García-Sánchez O., López-Hernández F.J., López-Novoa J.M. An integrative view on the role of TGF-β in the progressive tubular deletion associated to chronic kidney disease. Kidney Int 2010, 77:950-955.
74. Giardino I., Edelstein D., Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996, 97:1422-1428.
75. Gilbert R.E., Wu L.L., Kelly D.J., Cox A., Wilkinson-BERKa J.L., Johnston C.I., Cooper M.E. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 1999, 155:429-440.
76. Gobe G.C., Axelsen R.A. Genesis of renal tubular atrophy in experimental hydronephrosis in the rat. Role of apoptosis. Lab Invest 1987, 56:273-281.
77. Goldblatt H. The renal origin of hypertension. Physiol Rev 1947, 27:120-165.
78. Gonçalves S., Fernandez-Sanchez R., Sanchez-Niño M.D., Tejedor A., Neria F., Egido J., Ruiz-Ortega M., Ortiz A. Tyrphostins as potential therapeutic agents for acute kidney injury. Curr Med Chem 2010, 17:974-986.
79. Goncz K.K., Prokopishyn N.L., Chow B.L., Davis B.R., Gruenert D.C. Application of SFHR to gene therapy of monogenic disorders. Gene Ther 2002, 9:691-694.
80. Gonzalez-Avila G., Vadillo-Ortega F., Perez-Tamayo R. Experimental diffuse interstitial renal fibrosis. A biochemical approach. Lab Invest 1988, 59:245-252.
81. Grande M.T., Fuentes-Calvo I., Arévalo M., Heredia F., Santos E., Martínez-Salgado C., Rodríguez-Puyol D., Nieto M.A., López-Novoa J.M. Deletion of H-Ras decreases renal fibrosis and myofibroblast activation following ureteral obstruction in mice. Kidney Int 2010, 77:509-518.
82. Grande M.T., López-Novoa J.M. Therapeutical relevance of MAP-kinase inhibitors in renal diseases: Current knowledge and future clinical perspectives. Curr Med Chem 2008, 15:2054-2070.
83. Grande M.T., López-Novoa J.M. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 2009, 5:319-328.
84. Grande, M. T., Arévalo, M., Núñez, A., Cannata-Andía, J. B., Santos, E., López-Novoa, J. M. (2009). Targeted genomic disruption of H-ras and N-ras has no effect on early renal changes after unilateral ureteral ligation. World J Urol 27, 787-797.
85. Griffin K.A., Picken M.M., Churchill M., Churchill P., Bidani A.K. Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat. J Am Soc Nephrol 2000, 11:497-506.
86. Gruden G., Thomas S., Burt D., Lane S., Chusney G., Sacks S., Vibert G.C. Mechanical stretch induces vascular permeability factor in human mesangial cells: Mechanism of signal transduction. Proc Natl Acad Sci USA 1997, 94:12112-12116.
87. Gruden G., Zonca S., Hayward A., Thomas S., Maestrini S., Gnudi L., Vibert G.C. Mechanical stretch-induced fibronectin and transforming growth factor-β1 production in human mesangial cells in p38 mitogen-activated protein kinase-dependent. Diabetes 2000, 49:655-661.
88. Gupta S., Clarkson M.R., Duggan J., Brady H.R. Connective tissue growth factor: Potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000, 58:1389-1399.
89. Hammerman M.R. Tissue engineering the kidney. Kidney Int 2003, 63:1195-1204.
90. Hanss B., Bruggeman L.A. Applications of gene therapy to kidney disease. Curr Opin Nephrol Hypertens 2003, 12:439-445.
91. Heikkila P., Tibell A., Morita T., Chen Y., Wu G., Sado Y., Ninomiya Y., Pettersson E., Tryggvason K. Adenovirus-mediated transfer of type IV collagen alpha5 chain cDNA into swine kidney in vivo: Deposition of the protein into the glomerular basement membrane. Gene Ther 2001, 8:882-890.
92. Heilig C.W., Liu Y., England R.L., Freytag S.O., Gilbert J.D., Heilig K.O., Zhu M., Concepcion L.A., Brosius F.C. D-glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: Implications for diabetic nephropathy. Diabetes 1997, 46:1030-1039.
93. Helle F., Jouzel C., Chadjichristos C., Placier S., Flamant M., Guerrot D., François H., Dussaule J.C., Chatziantoniou C. Improvement of renal hemodynamics during hypertension-induced chronic renal disease: Role of EGF receptor antagonism. Am J Physiol Ren Physiol 2009, 297:F191-F199.
94. Herrera M.B., Bussolati B., Bruno S., Fonsato V., Romanazzi G.M., Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004, 14:1035-1341.
95. Herrero-Fresneda I., Torras J., Franquesa M., Vidal A., Cruzado J.M., Lloberas N., Fillat C., Grinyó J.M. HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int 2006, 70:265-274.
96. Hollenberg N.K. Implications of species difference for clinical investigation: Studies on the renin-angiotensin system. Hypertension 2000, 35:150-154.
97. Hollenberg N.K., Fisher N.D., Price D.A. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998, 32:387-392.
98. Hong C.Y., Hughes K., Chia K.S., Ng V., Ling S.L. Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diab Care 2003, 26:338-342.
99. Hostetter T.H., Olson J.L., Rennke H.G., Venkatachalam M.A., Brenner B.M. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981, 241:F85-F93.
100. Huang X.R., Chen W.Y., Truong L.D., Lan H.Y. Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003, 14:1738-1747.
101. Hughes J., Brown P., Shankland S.J. Cyclin kinase inhibitor p21CIP1/WAF1 limits interstitial cell proliferation following ureteric obstruction. Am J Physiol 1999, 277:F948-F956.
102. Humes H.D. Stem cells: The next therapeutic frontier. Trans Am Clin Climatol Assoc 2005, 116:167-183.
103. Humes H.D., Szczypka M.S. Advances in cell therapy for renal failure. Transpl Immunol 2004, 12:219-227.
104. Humes H.D., Weitzel W.F., Fissell W.H. Renal cell therapy in the treatment of patients with acute and chronic renal failure. Blood Purif 2004, 22:60-72.
105. Humphreys B.D., Duffield J.D., Bonventre J.V. Renal stem cells in recovery from acute kidney injury. Minerva Urol Nefrol 2006, 58:13-21.
106. Hunt S.C., Hasstedt S.J., Coon H., Camp N.J., Cawthon R.M., Wu L.L., Hopkins P.N. Linkage of creatinine clearance to chromosome 10 in Utah pedigrees replicates a locus for end-stage renal disease in humans and renal failure in the fawn-hooded rat. Kidney Int 2002, 62:1143-1148.
107. Ichikawi I., Harris R.C. Angiotensin actions in the kidney: Renewed insight into the old hormone. Kidney Int 1991, 40:583-596.
108. Imai E., Isaka Y. New paradigm of gene therapy: Skeletal-muscle-targeting gene therapy for kidney disease. Nephron 1999, 83:296-300.
109. Imai E., Isaka Y. Perspectives for gene therapy in renal diseases. Intern Med 2004, 43:85-96.
110. Imai E., Takabatake Y., Mizui M., Isaka Y. Gene therapy in renal diseases. Kidney Int 2004, 65:1551-1555.
111. Ingram A.J., Ly H., Thai K., Kang M., Scholey J.W. Activation of mesangial cell signaling cascades in response to mechanical strain. Kidney Int 1999, 55:476-485.
112. Inscho E.W., Imig J.D., Deichmann P.C., Cook A.K. Candesartan cilexetilprotects againsts loss of autoregulatory efficiency in angiotensin-II infused rats. J Am Soc Nephrol 1999, 10:S178-S183.
113. Ishidoya S., Morrissey J., McCracken R., Reyes A., Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995, 47:1285-1294.
114. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., Bursell S.E., Kern T.S., Ballas L.M., Heath W.F., Stramm L.E., Feener E.P., King G.L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272:728-731.
115. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110:341-350.
116. Jafar T.H., Schmid C.H., Landa M., Giatras I., Toto R., Remuzzi G., Maschio G., Brenner B.M., Kamper A., Zucchelli P., Becker G., Himmelmann A., Bannister K., Landais P., Shahinfar S., de Jong P.E., de Zeeuw D., Lau J., Levey A.S. Angiotensin-converting enzyme inhibitors and progression of nondiabetic kidney disease. A meta-analysis of patients-level data. Ann Intern Med 2001, 135:73-87.
117. Johnson R.J., Rodriguez-Iturbe B., Kang D.H., Feig D.I., Herrera-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens 2005, 18:431-440.
118. Johnson R.J., Rodriguez-Iturbe B., Nakagawa T., Kang D.H., Feig D.I., Herrera-Acosta J. Subtle renal injury is likely a common mechanism for salt-sensitive essential hypertension. Hypertension 2005, 45:326-330.
119. Julius S., Weber M.A., Kjeldsen S.E., McInnes G.T., Zanchetti A., Brunner H.R., Laragh J., Schork M.A., Hua T.A., Amerena J., Balazovjech I., Cassel G., Herczeg B., Koylan N., Magometschnigg D., Majahalme S., Martinez F., Oigman W., Seabra Gomes R., Zhu J.R. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: Outcomes in patients receiving monotherapy. Hypertension 2006, 48:385-391.
120. Kagami S., Border W.A., Miller D.E., Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431-2437.
121. Kahn S.A., Gulmi F.A., Chou S.Y., Mooppan U.M., Kim H. Contribution of endothelin-1 to renal vasoconstriction in unilateral ureteral obstruction: Reversal by verapamil. J Urol 1997, 157:1957-1962.
122. Kale S., Karihaloo A., Clark P.R., Kashgarian M., Krause D.S., Cantley L.G. Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J Clin Invest 2003, 112:42-49.
123. Kaneto H., Morrissey J., Klahr S. Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993, 44:313-321.
124. Kaneto H., Morrissey J., McCracken R., Reyes A., Klahr S. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int 1994, 45:1637-1647.
125. Kanwar Y.S., Akagi S., Sun L., Nayak B., Xie P., Wada J., Chugh S.S., Danesh F.R. Cell biology of diabetic kidney disease. Nephron Exp Nephrol 2005, 101:e100-e110.
126. Kellner D., Chen J., Richardson I., Seshan S.V., El Chaar M., Vaughan E.D., Poppas D., Felsen D. Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. J Urol 2006, 176:806-812.
127. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000, 52:11-34.
128. Kim K.H., Kim Y., Park H.W., Jeong H.J., Mauer M. A re-evaluation of the renal ablation model of progressive renal disease in rats. J Nephrol 2003, 16:196-202.
129. Kinuno H., Tomoda F., Koike T., Takata M., Inoue H. Effects of uninephrectomy on renal structural properties in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2005, 32:173-178.
130. Klahr S. Obstructive nephropathy. Kidney Int 1998, 54:286-300.
131. Klahr S., Morrissey J.J. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int Suppl 1997, 63:S111-S114.
132. Klahr S., Morrissey J.J. The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Semin Nephrol 1998, 18:622-632.
133. Klahr S., Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Ren Physiol 2002, 283:F861-F875.
134. Kline R.L., Liu F. Modification of pressure-natriuresis by long term losartan in spontaneously hypertensive rats. Hypertension 1994, 24:467-473.
135. Kohlstedt K., Brandes R.P., Muller-Esterl W., Busse R., Fleming I. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res 2004, 94:60-67.
136. Kohlstedt K., Busse R., Fleming I. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension 2005, 45:126-132.
137. Kohzuki M., Kanazawa M., Liu P.F., Kamimoto M., Yoshida K., Saito T., Yasujima M., Sato T., Abe K. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: Chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors. J Hypertens 1995, 13:1785-1790.
138. Korbling M., Estrov Z. Adult stem cells for tissue repair - A new therapeutic concept?. N Engl J Med 2003, 349:570-582.
139. Koya D., Jirousek M.R., Lin Y.W., Ishii H., Kuboki K., King G.L. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997, 100:115-126.
140. Krepinsky J.C., Li Y., Tang D., Liu L., Scholey J., Ingram A.J. Stretch-induced Raf-1 activation in mesangial cells requires actin cytoskeletal integrity. Cell Signal 2005, 17:311-320.
141. Kretzler M. Role of podocytes in focal sclerosis: Defining the point of no return. J Am Soc Nephrol 2005, 16:2830-2832.
142. Kretzler M., Koeppen-Hagemann I., Kriz W. Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat. Virchows Arch 1994, 425:181-193.
143. Kriz W., Hosser H., Hahnel B., Gretz N., Provoost A.P. From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: A histopathological study in rat models and human glomerulopathies. Nephrol Dial Transplant 1998, 13:2781-2798.
144. Lacolley P. Mechanical influence of cyclic stretch on vascular endothelial cells. Cardiovasc Res 2004, 63:577-579.
145. Lai L.W., Chan D.M., Erickson R.P., Hsu S.J., Lien Y.H. Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy. J Clin Invest 1998, 101:1320-1325.
146. Lange-Sperandio B., Cachat F., Thornhill B.A., Chevalier R.L. Selectins mediate macrophage infiltration in obstructive nephropathy in newborn mice. Kidney Int 2002, 61:516-524.
147. Lapsley M., Flynn F.V., Sansom P.A. Beta 2-glycoprotein-1 (apolipoprotein H) excretion and renal tubular malfunction in diabetic patients without clinical proteinuria. J Clin Pathol 1993, 46:465-469.
148. Lassila M., Seah K.K., Allen T.J., Thallas V., Thomas M.C., Candido R., Burns W.C., Forbes J.M., Calkin A.C., Cooper M.E., Jandeleit-Dahm K.A. Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role od advanced end products. J Am Soc Nephrol 2004, 15:2125-2138.
149. Lehmann R., Schleicher E.D. Molecular mechanism of diabetic nephropathy. Clin Chim Acta 2000, 297:135-144.
150. Lewis E.J. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens 2002, 15:123S-128S.
151. Lien Y.H., Lai L.W. Gene therapy for renal disorders. Expert Opin Biol Ther 2004, 4:919-926.
152. Lippin Y., Dranitzki-Elhalel M., Brill-Almon E., Mei-Zahav C., Mizrachi S., Liberman Y., Iaina A., Kaplan E., Podjarny E., Zeira E., Harati M., Casadevall N., Shani N., Galun E. Human erythropoietin gene therapy for patients with chronic renal failure. Blood 2005, 106:2280-2286.
153. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004, 15:1-12.
154. Ljutic D., Kes P. The role of arterial hypertension in the progression of non-diabetic glomerular disease. Nephrol Dial Transplant 2003, 18(Suppl 5):v28-v30.
155. Longaretti L., Benigni A. Endothelin receptor selectivity in chronic renal failure. Eur J Clin Invest 2009, 39(Suppl 2):32-37.
156. Lopez B., Ryan R.P., Moreno C., Sarkis A., Lazar J., Provoost A.P., Jacob H.J., Roman R.J. Identification of a QTL on chromosome 1 for impaired autoregulation of RBF in fawn-hooded hypertensive rats. Am J Physiol Ren Physiol 2006, 290:F1213-F1221.
157. López-Farré A., Bernabeu F., Gómez-Garre D., Ramon y Cajal S., Braquet P., López-Novoa J.M. Platelet-activating factor antagonists treatment protects against postischemic acute renal failure in rats. J Pharmacol Exp Ther 1990, 253:328-333.
158. Lopez-Hernandez F.J., Flores O., Lopez-Novoa J.M., Montero M.J., Carron R. Antihypertensive action of trandolapril and verapamil in spontaneously hypertensive rats after unilateral nephrectomy. J Cardiovasc Pharmacol 1998, 32:284-290.
159. López-Hernández F.J., López Novoa Potential utility of PPARalpha activation in the prevention of ischemic and drug-induced acute renal damage. Kidney Int 2009, 76:1022-1024.
160. López-Hernández F.J., López-Novoa J.M. The lord of the ring: Mandatory role of the kidney in drug therapy of hypertension. Pharmacol Ther 2006, 111:53-80.
161. López-Novoa J.M. Potential role of platelet activating factor in acute renal failure. Kidney Int 1999, 55:1672-1682.
162. Lorz C., Benito A., Ucero A.C., Santamaría B., Ortiz A. Trail and kidney disease. Front Biosci 2009, 14:3740-3749.
163. Loutzenhiser R., Griffin K., Williamson G., Bidani A. Renal autoregulation: New perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol 2006, 290:R1153-R1167.
164. Ma G., Allen T.J., Cooper M.E., Cao Z. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. Kidney Int 2004, 66:1090-1098.
165. Ma J., Nishimura H., Fogo A., Kon V., Inagami T., Ichikawa I. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 1998, 53:937-944.
166. MacKinnon M., Shurraw S., Akbari A., Knoll G.A., Jaffey J., Clark H.D. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 2006, 48:8-20.
167. Makino H., Kashihara N., Sugiyama H., Sekikawa T., Ota Z. Role of apoptosis in the progression of glomerulosclerosis. Contrib Nephrol 1996, 118:41-47.
168. Mangrum A.J., Bakris G.L. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol 2004, 24:168-175.
169. Martínez-Salgado C., Rodríguez-Peña A., López-Novoa J.M. Involvement of small Ras GTPases and its effectors in chronic renal disease. Cell Mol Life Sci 2008, 65:477-492.
170. Masson E., Lagarde M., Wiernsperger N., El Bawab S. Hyperglycemia and glucosamine-induced mesangial cell cycle arrest and hypertrophy: Common or independent mechanisms?. IUBMB Life 2006, 58:381-388.
171. Masuya M., Drake C.J., Fleming P.A., Reilly C.M., Zeng H., Hill W.D., Martin-Studdard A., Hess D.C., Ogawa M. Hematopoietic origin of glomerular mesangial cells. Blood 2003, 101:2215-2218.
172. Mattson D.L., Kunert M.P., Roman R.J., Jacob H.J., Cowley A.W. Substitution of chromosome 1 ameliorates l-NAME hypertension and renal disease in the fawn-hooded hypertensive rat. Am J Physiol Ren Physiol 2005, 288:F1015-F1022.
173. McPherson E.A., Luo Z., Brown R.A., LeBard L.S., Corless C.C., Speth R.C., Bagby S.P. Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2004, 15:493-500.
174. Mendelsohn C. Functional obstruction: The renal pelvis rules. J Clin Invest 2004, 113:957-959.
175. Menini S., Ricci C., Iacobini C., Bianchi G., Pugliese G., Pesce C. Glomerular number and size in Milan hypertensive and normotensive rats: Their relationship to susceptibility and resistance to hypertension and renal disease. J Hypertens 2004, 22:2185-2192.
176. Mertens P.R., Espenkott V., Venjakob B., Heintz B., Handt S., Sieberth H.G. Pressure oscillation regulates human mesangial cell growth and collagen synthesis. Hypertension 1998, 32:945-952.
177. Mire D.E., Silfani T.N., Pugsley M.K. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005, 46:585-593.
178. Miyake-Ogawa C., Miyazaki M., Abe K., Harada T., Ozono Y., Sakai H., Koji T., Kohno S. Tissue-specific expression of renin-angiotensin system components in IgA nephropathy. Am J Nephrol 2005, 25:1-12.
179. Miyazaki M., Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci 2006, 100:391-397.
180. Molitch M.E., DeFronzo R.A., Franz M.J., Keane W.F., Mogensen C.E., Parving H.H., Steffes M.W. American Diabetes Association: Nephropathy in diabetes. Diab Care 2004, 27(Suppl 1):S79-S83.
181. Moon J.A., Kim H.T., Cho I.S., Sheen Y.Y., Kim D.K. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006, 70:1234-1243.
182. Morikawa T., Imanishi M., Suzuki H., Okada N., Okumura M., Konishi Y., Yoshioka K., Takai S., Miyazaki M. Mast cell chymase in the ischemic kidney of severe unilateral renovascular hypertension. Am J Kidney Dis 2005, 45:e45-e50.
183. Morrissey J.J., Ishidoya S., McCracken R., Klahr S. Control of p53 and p21 (WAF1) expression during unilateral ureteral obstruction. Kidney Int Suppl 1996, 57:S84-S92.
184. + channel: Potential implications for the control of glomerular filtration. J Am Soc Nephrol 2004, 15:2981-2987.
185. Munger K.A., Montero A., Fukunaga M., Uda S., Yura T., Imai E., Kaneda Y., Valdivielso J.M., Badr K.F. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci USA 1999, 96:13375-13380.
186. Munusamy S., MacMillan-Crow L.A. Mitochondrial superoxide plays a crucial role in the development of mitochondrial dysfunction during high glucose exposure in rat renal proximal tubular cells. Free Radic Biol Med 2009, 46:1149-1157.
187. Nabokov A., Amann K., Gassmann P., Schwarz U., Orth S.R., Ritz E. The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 1998, 13:173-176.
188. Nakamura T., Obata J., Kuroyanagi R., Kimura H., Ikeda Y., Takano H., Naito A., Sato T., Yoshida Y. Involvement of angiotensin II in glomerulosclerosis of stroke-prone spontaneously hypertensive rats. Kidney Int Suppl 1996, 55:S109-S112.
189. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized controlled trial. Lancet 2003, 361:117-124.
190. Nathan S., Pepine C.J., Bakris G.L. Calcium antagonists. Effects on cardio-renal risk in hypertensive patients. Hypertension 2005, 46:637-642.
191. Neuringer J.R., Brenner B.M. Hemodynamic theory of progressive renal disease: A 10-year update in brief review. Am J Kidney Dis 1993, 22:98-104.
192. Ng Y.Y., Huang T.P., Yang W.C., Chen Z.P., Yang A.H., Mu W., Nikolic-Paterson D.J., Atkins R.C., Lan H.Y. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998, 54:864-876.
193. Nielsen B., Flyvbjerg A. Calcium channel blockers - The effect on renal changes in clinical and experimental diabetes: An overview. Nephrol Dial Transplant 2000, 15:581-585.
194. Nigbor D.A., Lewis J.B. Use of calcium antagonists in renal patients: Therapeutic benefit or medical malpractice?. Curr Hypertens Rep 2003, 5:430-436.
195. Noel L.H. Morphological features of primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1999, 14:53-57.
196. Odelberg S.J. Inducing cellular dedifferentiation: A potential method for enhancing endogenous regeneration in mammals. Semin Cell Dev Biol 2002, 13:335-343.
197. Oh T.K., Quan G.H., Kim H.Y., Park F., Kim S.T. Correction of anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene. Am J Nephrol 2006, 26:326-334.
198. Oliver J.A., Maarouf O., Cheema F.H., Martens T.P., Al-Awqati Q. The renal papilla is a niche for adult kidney stem cells. J Clin Invest 2004, 114:795-804.
199. Ophascharoensuk V., Fero M.L., Hughes J., Roberts J.M., Shankland S.J. The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat Med 1998, 4:575-580.
200. Ophascharoensuk V., Giachelli C.M., Gordon K., Hughes J., Pichler R., Brown P., Liaw L., Schmidt R., Shankland S.J., Alpers C.E., Couser W.G., Johnson R.J. Obstructive uropathy in the mouse: Role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999, 56:571-580.
201. Orasanu G., Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009, 53(Suppl S):S35-S42.
202. Palm F., Cederberg J., Hansell P., Liss P., Carlsson P.O. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 2003, 46:1153-1160.
203. Palmer B.F. Disturbances in renal autoregulation and the susceptibility to hypertension-induced chronic kidney disease. Am J Med Sci 2004, 328:330-343.
204. Passier R., Mummery C. Origin and use of embryonic and adult stem cells in differentiation and tissue repair. Cardiovasc Res 2003, 58:324-335.
205. Patschan D., Plotkin M., Goligorsky M.S. Therapeutic use of stem and endothelial progenitor cells in acute renal injury: Ça ira. Curr Opin Pharmacol 2006, 6:176-183.
206. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., Marks R.G., Kowey P., Messerli F.H., Mancia G., Cangiano J.L., Garcia-Barreto D., Keltai M., Erdine S., Bristol H.A., Kolb H.R., Bakris G.L., Cohen J.D., Parmley W.W., Investigators I.N.V.E.S.T. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003, 290:2805-2816.
207. Perico N., Benigni A., Remuzzi G. Present and future drug treatments for chronic kidney diseases: Evolving targets in renoprotection. Nat Rev Drug Discov 2008, 7:936-953.
208. Persson P.B. Renal blood flow autoregulation in blood pressure control. Curr Opin Nephrol Hypertens 2002, 11:67-72.
209. Petermann A.T., Hiromura K., Blonski M., Pippin J., Monkawa T., Durvasula R., Couser W.G., Shankland S.J. Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 2002, 61:40-50.
210. Petermann A.T., Pippin J., Durvasula R., Pichler R., Hiromura K., Monkawa T., Couser W.G., Shankland S.J. Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 2005, 67:157-166.
211. Pimentel J.L., Sundell C.L., Wang S., Kopp J.B., Montero A., Martinez-Maldonado M. Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy. Kidney Int 1995, 48:1233-1246.
212. Pires M.J., Rodríguez-Peña A.B., Arévalo M., Cenador B., Evangelista S., Esteller A., Sánchez-Rodríguez A., Colaço A., López-Novoa J.M. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. J Hypertens 2007, 25:2486-2496.
213. Pohl M.A., Blumenthal S., Cordonnier D.J., De Alvaro F., Deferrari G., Eisner G., Esmatjes E., Gilbert R.E., Hunsicker L.G., de Faria J.B., Mangili R., Moore J., Reisin E., Ritz E., Schernthaner G., Spitalewitz S., Tindall H., Rodby R.A., Lewis E.J. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J Am Soc Nephrol 2005, 16:3027-3037.
214. Price K.D., Price C.S., Reynolds R.D. Hyperglycemia-induced ascorbic acid deficiency promotes endothelial dysfunction and the development of atherosclerosis. Atherosclerosis 2001, 158:1-12.
215. Prieto M., Rodríguez-Peña A., Arévalo M., Rivas J.V., Düwel A., Eleno N., Sánchez R.J., Morales A.I., López-Novoa J.M., Pérez-Barriocanal F. Effect of the long-term treatment with trandolapril on endoglin expression in rats with experimental renal fibrosis induced by renal mass reduction. Kidney Blood Press Res 2005, 28:32-40.
216. Pugsley M.K. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc West Pharmacol Soc 2005, 48:35-38.
217. Rahn K.H. The role of calcium antagonists in patients with chronic renal failure. Pediatr Nephrol 2005, 20:1208-1213.
218. Reddy G.R., Kotlyarevska K., Ransom R.F., Menon R.K. The podocyte and diabetes mellitus: Is the podocyte the key to the origins of diabetic nephropathy?. Curr Opin Nephrol Hypertens 2008, 17:32-36.
219. Remuzzi G., Benigni A., Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006, 116:288-296.
220. Reverte M., Flores O., Gallego B., Leston A., Lopez-Novoa J.M. Effect of chronic NG-nitro-l-arginine methyl ester (l-NAME) on blood pressure and renal function in conscious uninephrectomized spontaneously hypertensive rats. Can J Physiol Pharmacol 1998, 76:63-67.
221. Richard V., Hurel-Merle S., Scalbert E., Ferry G., Lallemand F., Bessou J.P., Thuillez C. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 2001, 104:750-752.
222. Ricker J.L., Mata J.E., Iversen P.L., Gattone V.H. c-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int 2002, 61(Suppl 1):125-131.
223. Riser B.L., Cortes P., Yee J., Sharba A.K., Asano K., Rodriguez-Barbero A., Narins R.G. Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF-beta. J Am Soc Nephrol 1998, 9:827-836.
224. Riser B.L., Ladson-Wofford S., Sharba A., Cortes P., Drake K., Guerin C.J., Yee J., Choi M.E., Segarini P.R., Narins R.G. TGF-beta receptor expression and binding in rat mesangial cells: Modulation by glucose and cyclic mechanical strain. Kidney Int 1999, 56:428-439.
225. Ritz E. Chymase: A potential culprit in diabetic nephropathy?. J Am Soc Nephrol 2003, 14:1952-1954.
226. Rodriguez-Barbero A., Bosque E., Rivas-Cabaero L., Arévalo M., López-Novoa J.M. Effect of platelet activating factor antagonist treatment on gentamicin nephrotoxicity. Mediat Inflamm 1992, 1:23-26.
227. Rodriguez-Barbero A., López-Novoa J.M., Arévalo M. Involvement of platelet-activating factor in gentamicin nephrotoxicity in rats. Exp Nephrol 1997, 5:47-54.
228. Rodriguez-Iturbe B., Vaziri N.D., Herrera-Acosta J., Johnson R.J. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: All for one and one for all. Am J Physiol Ren Physiol 2004, 286:F606-F616.
229. Rodriguez-Lopez A.M., Flores O., Arevalo M.A., Lopez-Novoa J.M. Glomerular cell proliferation and apoptosis in uninephrectomized spontaneously hypertensive rats. Kidney Int Suppl 1998, 68:S36-S40.
230. Rodriguez-Lopez A.M., Flores O., Arevalo M.A., Lopez-Novoa J.M. Tubular cell apoptosis and proliferation in the early phase of renal damage in uninephrectomized SHR. Kidney Blood Press Res 2002, 25:13-19.
231. Rodriguez-Peña A., Eleno N., Duwell A., Arevalo M., Perez-Barriocanal F., Flores O., Docherty N., Bernabeu C., Letarte M., Lopez-Novoa J.M. Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension 2002, 40:713-720.
232. Rodríguez-Peña A.B., Grande M.T., Eleno N., Arévalo M., Guerrero C., Santos E., López-Novoa J.M. Activation of Erk1/2 and Akt following unilateral ureteral obstruction. Kidney Int 2008, 74:196-209.
233. Rodriguez-Peña A., Prieto M., Duwel A., Rivas J.V., Eleno N., Perez-Barriocanal F., Arevalo M., Smith J.D., Vary C.P., Bernabeu C., Lopez-Novoa J.M. Up-regulation of endoglin, a TGF-β-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction. Nephrol Dial Transplant 2001, 16:34-39.
234. Rookmaaker M.B., Verhaar M.C., van Zonneveld A.J., Rabelink T.J. Progenitor cells in the kidney: Biology and therapeutic perspectives. Kidney Int 2004, 66:518-522.
235. Rosario R.F., Wesson D.E. Primary hypertension and nephropathy. Curr Opin Nephrol Hypertens 2006, 15:130-134.
236. Rouschop K.M., Sewnath M.E., Claessen N., Roelofs J.J., Hoedemaeker I., van der Neut R., Aten J., Pals S.T., Weening J.J., Florquin S. CD44 deficiency increases tubular damage but reduces renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 2004, 15:674-686.
237. Ruiz-Ortega M., Lorenzo O., Ruperez M., Blanco J., Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol 2001, 158:1743-1756.
238. Ruiz-Ortega M., Lorenzo O., Ruperez M., Konig S., Wittig B., Egido J. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: Molecular mechanisms. Circ Res 2000, 86:1266-1272.
239. Ruiz-Ortega M., Lorenzo O., Ruperez M., Suzuki Y., Egido J. Angiotensin II activates nuclear transcription factor-kappaB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. Nephrol Dial Transplant 2001, 16(Suppl 1):27-33.
240. Sadjadi J., Kramer G.L., Yu C.H., Burress Welborn M., Chappell M.C., Gregory Modrall J. Angiotensin converting enzyme-independent angiotensin ii production by chymase is up-regulated in the ischemic kidney in renovascular hypertension. J Surg Res 2005, 127:65-69.
241. Sanchez-Lozada L.G., Tapia E., Johnson R.J., Rodriguez-Iturbe B., Herrera-Acosta J. Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney Int Suppl 2003, 86:S9-S14.
242. Sassard J., Lo M., Liu K.L. Lyon genetically hypertensive rats: An animal model of "low renin hypertension". Acta Pharmacol Sin 2003, 24:1-6.
243. Satoh M., Kashihara N., Yamasaki Y., Maruyama K., Okamoto K., Maeshima Y., Sugiyama H., Sugaya T., Murakami K., Makino H. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2001, 12:317-325.
244. Schachinger V., Zeiher A.M. Stem cells and cardiovascular and renal disease: Today and tomorrow. J Am Soc Nephrol 2005, 16(Suppl 1):S2-S6.
245. Schena F.P., Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005, 16:S30-S33.
246. Schiffer M., Bitzer M., Roberts I.S., Kopp J.B., ten Dijke P., Mundel P., Bottinger E.P. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001, 108:807-816.
247. Schreiner G.F., Harris K.P., Purkerson M.L., Klahr S. Immunological aspects of acute ureteral obstruction: Immune cell infiltrate in the kidney. Kidney Int 1988, 34:487-493.
248. Schreiner G.F., Kohan D.E. Regulation of renal transport processes and hemodynamics by macrophages and lymphocytes. Am J Physiol 1990, 258:F761-F767.
249. Schreiner G.F., Unanue E.R. Origin of the rat mesangial phagocyte and its expression of the leukocyte common antigen. Lab Invest 1984, 51:515-523.
250. Sealey J.E., Blumenfeld J.D., Bell G.M., Pecker M.S., Sommers S.C., Laragh J.H. On the renal basis of essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertens 1988, 6:763-777.
251. Seccia T.M., Belloni A.S., Guidolin D., Sticchi D., Nussdorfer G.G., Pessina A.C., Rossi G.P. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. J Hypertens 2006, 24:1419-1427.
252. Segura J., García-Donaire J.A., Ruilope L.M. Calcium channel blockers and renal protection: Insights from the latest clinical trials. J Am Soc Nephrol 2005, 16(Suppl 1):S64-S66.
253. Sercombe R., Vicaut E., Oudart N., Sercombe C., Girard P. Acetylcholine-induced relaxation of rabbit basilar artery in vitro is rapidly reduced by reactive oxygen species in acute hyperglycemia: Role of NADPH oxidase. J Cardiovasc Pharmacol 2004, 44:507-516.
254. Shahinfar S., Lyle P.A., Zhang Z., Keane W.F., Brenner B.M. Losartan: Lessons learned from the RENAAL study. Expert Opin Pharmacother 2006, 7:623-630.
255. Shappell S.B., Mendoza L.H., Gurpinar T., Smith C.W., Suki W.N., Truong L.D. Expression of adhesion molecules in kidney with experimental chronic obstructive uropathy: The pathogenic role of ICAM-1 and VCAM-1. Nephron 2000, 85:156-166.
256. Sica D.A. Pharmacotherapy review: Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2005, 7:485-488.
257. Sica D.A. Angiotensin receptor blockers: New considerations in their mechanism of action. J Clin Hypertens (Greenwich) 2006, 8:381-385.
258. Singh R., Barden A., Mori T., Beilin L. Advanced glycation endproducts: A review. Diabetology 2001, 44:129-146.
259. Singh D.K., Winocour P., Farrington K. Mechanisms of disease: The hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 2008, 4:216-226.
260. Sommers S.C., Relman A.S., Smithwick R.H. Histologic studies of kidney biopsy specimens from patients with hypertension. Am J Pathol 1958, 34:685-715.
261. Song J.H., Cha S.H., Hong S.B., Kim D.H. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens Suppl 2006, 24:S101-S106.
262. St Lezin E., Griffin K.A., Picken M., Churchill M.C., Churchill P.C., Kurtz T.W., Liu W., Wang N., Kren V., Zidek V., Pravenec M., Bidani A.K. Genetic isolation of a chromosome 1 region affecting susceptibility to hypertension-induced renal damage in the spontaneously hypertensive rat. Hypertension 1999, 34:187-191.
263. Stoll M., Jacob H.J. Genetic rat models of hypertension: relationship to human hypertension. Curr Hypertens Rep 2001, 3:157-164.
264. Suganuma E., Zuo Y., Ayabe N., Ma J., Babaev V.R., Linton M.F., Fazio S., Ichikawa I., Fogo A.B., Kon V. Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. J Am Soc Nephrol 2006, 17:433-441.
265. Sugimoto H., Shikata K., Matsuda M., Kushiro M., Hayashi Y., Hiragushi K., Wada J., Makino H. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998, 41:1426-1434.
266. Susztak K., Raff A.C., Schiffer M., Bottinger E.P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006, 55:225-233.
267. Szczech L.A., Lazar I.L. Projecting the United States ESRD population: Issues regarding treatment of patients with ESRD. Kidney Int Suppl 2004, 90:S3-S7.
268. Takahashi T., Kalka C., Masuda H., Chen D., Silver M., Kearney M., Magner M., Isner J.M., Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999, 5:434-438.
269. Tanaka Y., Nagai M., Date T., Okada T., Abe Y., Seki S., Taniguchi M., Taniguchi I., Mochizuki S. Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. Hypertens Res 2004, 27:865-875.
270. Tawfik A., Jin L., Banes-Berceli A.K., Caldwell R.B., Ogbi S., Shirley A., Barber D., Catravas J.D., Stern D.M., Fulton D., Caldwell R.W., Marrero M.B. Hyperglycemia and reactive oxygen species mediate apoptosis in aortic endothelial cells through Janus kinase 2. Vascul Pharmacol 2005, 43:320-326.
271. Tesch G.H., Nikolic-Paterson D.J. Recent insights into experimental mouse models of diabetic nephropathy. Nephron Exp Nephrol 2006, 104:e57-e62.
272. Thomas M.C., Burns W.C., Cooper M.E. Tubular changes in early diabetic nephropathy. Adv Chron Kidney Dis 2005, 12:177-186.
273. Thomas G.L., Yang B., Wagner B.E., Savill J., El Nahas A.M. Cellular apoptosis and proliferation in experimental renal fibrosis. Nephrol Dial Transplant 1998, 13:2216-2226.
274. Thomson S.C., Vallon V., Blantz R.C. Kidney function in early diabetes: The tubular hypothesis of glomerular filtration. Am J Physiol Ren Physiol 2006, 286:F8-F15.
275. Torras J., Cruzado J.M., Riera M., Condom E., Duque N., Herrero I., Merlos M., Espinosa L., Lloberas N., Egido J., Grinyó J.M. Long-term protective effect of UR-12670 after warm renal ischemia in uninephrectomized rats. Kidney Int 1999, 56:1798-1808.
276. Touyz R.M., Schiffrin E.L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000, 52:639-672.
277. Tracy R.E., Mercante D.E., Moncada A., Berenson G. Quantitation of hypertensive nephrosclerosis on an objective rational scale of measure in adults and children. Am J Clin Pathol 1986, 85:312-318.
278. Truong L.D., Petrusevska G., Yang G., Gurpinar T., Shappell S., Lechago J., Rouse D., Suki W.N. Cell apoptosis and proliferation in experimental chronic obstructive uropathy. Kidney Int 1996, 50:200-207.
279. Tschope C., Seidi U., Reinecke A., Riester U., Graf K., Schultheiss H.P., Hilgenfeldt U., Unger T. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy. Int Immunopharmacol 2003, 3:335-344.
280. Tsouli S.G., Liberopoulos E.N., Kiortsis D.N., Mikhailidis D.P., Elisaf M.S. Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: A review of the current evidence. J Cardiovasc Pharmacol Ther 2006, 11:1-15.
281. Turkstra E., Braam B., Koomans H.A. Impaired renal blood flow autoregulation in two-kidney, one-clip hypertensive rats is caused by enhanced activity of nitric oxide. J Am Soc Nephrol 2000, 11:847-855.
282. U.S.Renal Data System, USRDS Annual data report: Atlas of end-stage renal disease in the United States 2005, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, http://www.usrds.org/atlas.htm.
283. U.S.Renal Data System, USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States 2009, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, http://www.usrds.org/2009/slides/indiv/INDEX_CKD.HTML.
284. Urata H., Strobel F., Ganten D. Widespread tissue distribution of human chymase. J Hypertens Suppl 1994, 12:S17-S22.
285. Van Dijk S.J., Specht P.A., Lazar J., Jacob H.J., Provoost A.P. Renal damage susceptibility and autoregulation in RF-1 and RF-5 congenic rats. Nephron Exp Nephrol 2005, 101:59-66.
286. Van Dijk S.J., Specht P.A., Lazar J., Jacob H.J., Provoost A.P. Absence of an interaction between the Rf-1 and Rf-5 QTLs influencing susceptibility to renal damage in rats. Nephron Exp Nephrol 2006, 104:96-102.
287. Van Dokkum R.P., Jacob H.J., Provoost A.P. Difference in susceptibility of developing renal damage in normotensive fawn-hooded (FHL) and August x Copenhagen Irish (ACI) rats after N(omega)-nitro-l-arginine methyl ester induced hypertension. Am J Hypertens 1997, 10:1109-1116.
288. Van Dokkum R.P., Jacob H.J., Provoost A.P. Genetic differences define severity of renal damage after l-NAME-induced hypertension in rats. J Am Soc Nephrol 1998, 9:363-371.
289. Van Dokkum R.P., Jacob H.J., Provoost A.P. Blood pressure and the susceptibility to renal damage after unilateral nephrectomy and l-NAME-induced hypertension in rats. Nephrol Dial Transplant 2000, 15:1337-1343.
290. Van Rodijnen W.F., van Lambalgen T.A., Tangelder G.J., van Dokkum R.P., Provoost A.P., ter Wee P.M. Reduced reactivity of renal microvessels to pressure and angiotensin II in fawn-hooded rats. Hypertension 2002, 39:111-115.
291. Veiraiah A. Hyperglycemia, lipoprotein glycation, and vascular disease. Angiology 2005, 56:431-438.
292. Verzola D., Bertolotto M.B., Villaggio B., Ottonello L., Dallegri F., Salvatore F., Berruti V., Gandolfo M.T., Garibotto G., Deferrari G. Oxidative stress mediates apoptotic changes induced by hyperglycemia in human tubular kidney cells. J Am Soc Nephrol 2004, 15(Suppl 1):S85-S87.
293. Wang X., Ajikobi D.O., Salevsky F.C., Cupples W.A. Impaired myogenic autoregulation in kidneys of Brown Norway rats. Am J Physiol Ren Physiol 2000, 278:F962-F969.
294. Wang A., Hascall V.C. Hyaluronan structures synthesized by rat mesangial cells in response to hyperglycemia induce monocyte adhesion. J Biol Chem 2004, 279:10279-10285.
295. Wang J.H., Thampatty B.P. An introductory review of cell mechanobiology. Biomech Model Mechanobiol 2006, 5:1-16.
296. Watanabe M., Nishikawa T., Takagi T., Kamiyama Y., Tamura Y., Kumagai A. Mechanism of suppressed renin-angiotensin system in spontaneously hypertensive rat (SHR). Clin Exp Hypertens A 1983, 5:49-70.
297. Wei C.C., Tian B., Perry G., Meng Q.C., Chen Y.F., Oparil S., Dell'Italia L.J. Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am J Physiol Heart Circ Physiol 2002, 282:H2254-H2258.
298. Weichert W., Paliege A., Provoost A.P., Bachmann S. Upregulation of juxtaglomerular NOS1 and COX-2 precedes glomerulosclerosis in fawn-hooded hypertensive rats. Am J Physiol Ren Physiol 2001, 280:F706-F714.
299. Weigert C., Sauer U., Brodbeck K., Pfeiffer A., Haring H.U., Schleicher E.D. AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells. J Am Soc Nephrol 2000, 11:2007-2016.
300. Weir M.R., Rosenberger C., Fink J.C. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001, 14:963-968.
301. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., Bucciarelli L.G., Rong L.L., Moser B., Markowitz G.S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P.P., Stern D.M., D'Agati V.D., Schmidt A.M. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2004, 162:1123-1137.
302. Wiederkehr M., Toto R., Fenves A.Z., Ram C.V. Hypertension and the kidney. Semin Nephrol 2005, 25:236-245.
303. Winkelmayer W.C., Weinstein M.C., Mittleman M.A., Glynn R.J., Pliskin J.S. Health economic evaluations: The special case of end stage renal disease treatment. Med Decis Mak 2002, 22:417-430.
304. Wolf G., Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 2005, 67:799-812.
305. Wolf G., Wenzel U., Burns K.D., Harris R.C., Stahl R.A., Thaiss F. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 2002, 61:1986-1995.
306. Wolf G., Ziyadeh F.N. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007, 106:p26-p31.
307. Wu L.L., Yang N., Roe C.J., Cooper M.E., Gilbert R.E., Atkins R.C., Lan H.Y. Macrophage and myofibroblast proliferation in remnant kidney: role of angiotensin II. Kidney Int Suppl 1997, 63:S221-S225.
308. Xue J.L., Ma J.Z., Louis T.A., Collins A.J. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001, 12:2753-2758.
309. Yamori Y., Nara Y., Tagami M., Mano M., Kihara M., Fujiwara K., Horie R., Kamino K. Common cellular disposition to hypertension and atherosclerosis. J Hypertens Suppl 1984, 2:S213-S215.
310. Yang J., Dai C., Liu Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002, 13:2464-2477.
311. Yang J., Dai C., Liu Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002, 13:2464-2477.
312. Yang H.Y., Erdos E.G., Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970, 214:374-376.
313. Yang J., Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001, 159:1465-1475.
314. Yang J., Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002, 13:96-107.
315. Yang J., Shultz R.W., Mars W.M., Wegner R.E., Li Y., Dai C., Nejak K., Liu Y. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002, 110:1525-1538.
316. Yokota K., Kishida M., Ogura T., Suzuki J., Otsuka F., Mimura Y., Takeda M., Nakamura Y., Makino H. Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension. Hypertens Res 2003, 26:265-272.
317. Yoon K., Igoucheva O., Alexeev V. Expectations and reality in gene repair. Nat Biotechnol 2002, 20:1197-1198.
318. Young L.S., Hegarty N.J., Fitzpatrick J.M. Obstructive uropathy. Curr Opin Urol 1998, 8:119-124.
319. Yu Y., Lyons T.J. A lethal tetrad in diabetes: Hyperglycemia, dyslipidemia, oxidative stress, and endothelial dysfunction. Am J Med Sci 2005, 330:227-232.
320. Zhang L., Edwards D.G., Berecek K.H. Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY). Clin Exp Hypertens 1996, 18:201-226.
321. Ziyadeh F.N., Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diab Rev 2008, 4:39-45.
322. Zou L., Imig J.D., Von Thun A.M., Hymel A., Ono H., Navar L.G. Receptor-mediated intrarenal ANG II augmentation in ANG II-infused rats. Hypertension 1996, 28:669-677.
323. Zurova-Nedelcevova J., Navarova J., Drabikova K., Jancinova V., Petrikova M., Bernatova I., Kristova V., Snirc V., Nosalova V., Sotnikova R. Participation of reactive oxygen species in diabetes-induced endothelial dysfunction. Neuro Endocrinol Lett 2006, 27(Suppl 2):168-171.